Methods and kits for diagnosing and monitoring hematopoietic cancers
OwnerIris Pecker, Israel Vlodavsky +6inventors
InventorsIris Pecker, Israel Vlodavsky, Ben Zion Katz, Amiram Eldor, Menachem Bitan, Aaron Polliack, Arnon Nagler, Zofia Eldor
Life of this patent
Estimating the term…
Abstract
Methods and kits for distinguishing between heparanase expressing and heparanase non-expressing hematopoietic cells, particularly useful in distinguishing between different types of differentiated and/or undifferentiated lymphomas and leukemias. The methods and kits are designed to detect heparanase expression, or absence thereof, at the gene, protein and/or protein activity levels.
Claims98
A method of distinguishing between heparanase expressing hematopoietic cells and heparanase non-expressing hematopoietic cells in subject in need thereof, the method comprising monitoring heparanase expression in hematopoietic cells obtained from the subject and, based on a presence or an absence of said heparanase expression, distinguishing between said heparanase expressing hematopoietic cells and said heparanase non-expressing hematopoietic cells.
A kit for distinguishing between heparanase expressing hematopoietic cells and heparanase non-expressing hematopoietic cells, comprising at least one container including at least one reagent for determining a level of heparanase expression or activity in a biological sample, and packaging material identifying said at least one reagent for use in distinguishing between heparanase expressing hematopoietic cells and heparanase non-expressing hematopoietic cells.
An improvement in a process of diagnosing acute myelogenous leukemia, the improvement comprising determining whether cells suspected as leukemic cells express heparanase, wherein heparanase expression is indicative of acute myelogenous leukemia.
A method for ascertaining the suitability of an anti-neoplastic drug candidate for efficacy in treating acute myelogenous leukemia, wherein said method comprises combining said candidate drug with a cell having an acute myelogenous leukemia phenotype, said cell being isolated or in a biological sample and detecting in said cell or biological sample a change in heparanase expression.
A kit for distinguishing between heparanase expressing acute myeloid leukemic cells and heparanase non-expressing neoplastic or normal hematopoietic cells, comprising at least one container including at least one reagent for determining a level of heparanase expression or activity in a biological sample, and packaging material identifying said at least one reagent for use in distinguishing between heparanase expressing acute myeloid leukemic cells and heparanase non-expressing neoplastic or normal hematopoietic cells.
An improvement in a process of diagnosing relapse in acute lymphocytic leukemia, the improvement comprising determining whether cells suspected as leukemic cells express heparanase, wherein heparanase expression is indicative of relapse of acute lymphocytic leukemia.
An improvement in a process of diagnosing chronic myelogenous leukemia, the improvement comprising determining whether cells suspected as leukemic cells express heparanase, wherein non-expression of heparanase is indicative of diagnosing chronic myelogenous leukemia.
A kit for distinguishing between heparanase expressing neoplastic or normal hematopoietic cells and heparanase non-expressing chronic myeloid leukemic cells, comprising at least one container including at least one reagent for determining a level of heparanase expression or activity in a biological sample, and packaging material identifying said at least one reagent for use in distinguishing between heparanase expressing neoplastic or normal hematopoietic cells and heparanase non-expressing chronic myeloid leukemic cells.
Dependencies are inferred from the claim text.